Healthcare Reports

Nurture is as important as nature when it comes to IVF, scientists find…

Posted on Updated on

UK IVF Services Market

According to a new report published by Allied Market Research titled, UK IVF Services Market by End User and Cycle Type: Opportunity Analysis and Industry Forecast, 2014-2022, the UK IVF services market is estimated to reach $685.4 million by 2022, registering a CAGR of 7.7% from 2016 to 2022.

Early Buyers will receive 20% customization on this report.

The UK IVF services market is characterized by important factors such as increase in cases of infertility, delayed marriages, and parenthood decisions. In addition, decrease in birthrate also boost the market growth. For instance, in 2014 total fertility rate decreased to 1.83 per woman from 1.85 in 2013. The IVF services market in the UK is anticipated to experience a continuous growth due to supportive regulatory bodies such as Human Fertilization and Embryo authority (HFEA), which closely regulates the functioning of IVF treatments and research involving human embryos in the UK supplements the market growth. The growth of the market is associated with decrease in birthrate, increase in infertility, and supportive regulations for IVF treatments.

Sample Report, Click Here!!

The fertility clinics segment is anticipated to dominate the market during the forecast period in terms of volume and revenue. This is because the fertility clinics provide technologically advanced and wide range of fertility treatments under one roof for patients.

Key Findings of the UK IVF Services Market:

  • Based on cycle type, fresh IVF cycles (non-donor) is projected to be one of the fastest growing segment at a CAGR of 8.3% from 2016 to 2022, in terms of revenue
  • Based on end users, fertility clinics is projected to be the one of the fastest growing segment at a CAGR of 8.9% from 2016 to 2022, in terms of revenue
  • Based on cycle type, fresh IVF cycle (non-donor) is projected to be the one of the fastest growing segment at a CAGR of 7.6% from 2016 to 2022, in terms of volume
  • Based on end users, fertility clinics is projected to be the one of the fastest growing segment at a CAGR of 8.2% from 2016 to 2022, in terms of volume

Key players in the UK IVF services market includes companies, hospitals, surgical centers, fertility centers, and clinical research institutes. These includes Lister Fertility Clinics, The Bridge center, and Chelsea and Westminster Hospital.

Growth Drivers Overview in the Acute Ischemic Stroke Diagnosis and Treatment Market by 2022

Posted on Updated on

www.alliedmarketresearch.com Include New Market Research Report “World Acute Ischemic Stroke Diagnosis and Treatment Market” Attractiveness, Competitive Landscape and Forecasts to Its Huge Collection Of Research Reports.

Ischemic stroke is caused by a dysfunction in the supply of blood to the brain due to emboli, thrombus or atherosclerosis occurring in cerebral arteries. According to a World Health Organization (WHO) estimate, around 17 million people die every year due to cardiovascular diseases. Heart attacks and strokes respectively account for the highest number of deaths due to cardiovascular diseases, globally. The statistics of the Centres for Disease Control and Prevention suggest that about 87% of all strokes are ischemic strokes. Stroke is one of the leading cause of long term disability, occurring at a higher rate in the old age population. Moreover, stroke leads to 1 out of every 20 deaths, costing around $34 billion to U.S. annually. Higher rates of mortality associated with strokes highlight an impending need for innovative drugs and diagnostic devices.

Request sample report @ https://www.alliedmarketresearch.com/request-toc-and-sample/1440

The two major factors propelling the growth of the acute ischemic stroke diagnosis and treatment market are; large patient pools and a concerning rise in population at a higher risk of developing stroke in the near future. Rising incidence of diabetes along with heavy tobacco users and an increase in the ageing population are significant factors that determine the market growth. However, the high cost of treatment, lack of transparent reimbursement policies, and limited availability of expertise; are likely to restrict the market growth.

Enquire about report: https://www.alliedmarketresearch.com/purchase-enquiry/1440

The global ischemic stroke diagnosis and treatment market is segmented on the basis of type and geography. According to type, the market is segmented into, diagnostics and therapeutics. The diagnostic market is further segmented into Computed Tomography Scan (CT scan), Magnetic Resonance Imaging (MRI), Carotid Ultrasound, Cerebral Angiography, Electrocardiography, Echocardiography and Blood tests. The therapeutic market further segments into Tissue Plasminogen Activator Anticoagulant, Antiplatelet and Antihypertensive. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific, and LAMEA.

Connect to Analyst: https://www.alliedmarketresearch.com/connect-to-analyst/1440

New Product launches and collaborations are some of the key strategies adopted by leading industry players. In March, 2015, FDA approved WATCHMAN, a left atrial appendage closure device designed to prevent stroke in patients with atrial fibrillation. Silk Road Medical, Inc. has launched an Anti-Stroke Enroute Device, a transcarotid neuroprotection system, designed to access the common carotid artery through a minimally invasive technique. NeuroVive Pharmaceutical AB, entered into collaboration with BBB Therapeutics, for development of the NVP014 drug candidate used in the treatment of ischemic strokes.

The companies profiled in this report include, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Cordis Corporation, Koninklijke Philips N.V., GE Healthcare, Siemens AG, Stryker Corporation, Genentech, Inc. and Merck & Co., Inc.

Browse full report @ https://www.alliedmarketresearch.com/acute-ischemic-stroke-diagnosis-and-treatment-market

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions”. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Human Insulin Market: Segmentation & Coverage

Posted on Updated on

www.alliedmarketresearch.com Include New Market Research Report “Human Insulin Market” Attractiveness, Competitive Landscape and Forecasts to Its Huge Collection Of Research Reports.

Insulin regulates fat and carbohydrate metabolism in the body. It is a peptide hormone, which is secreted in the pancreas by beta cells of the islets of Langerhans and it helps to regulate the glucose metabolism. It causes skeletal muscle cells and fat tissues to absorb glucose from the blood. The global human insulin market is expected to grow at healthy CAGR during the forecast period due to high prevalence of diabetes, worldwide. In-depth analysis of the global human insulin market focuses on various aspects of the market such as market trends, market drivers, restraints and opportunities. Competitive landscape section focuses on key leaders within the global human insulin market and their major growth strategies. Detailed analysis of segments helps in understanding market dynamics and would be beneficial for market professionals.

Request sample report @ https://www.alliedmarketresearch.com/request-toc-and-sample/417

The growth of global human insulin market is primarily attributed to rising prevalence of diabetes. The factors that contribute to growing number of diabetic patient globally include changes in lifestyles, growing number of obese as well as geriatric population and inadequate healthcare services. Favorable government policies and technological advances such as innovation of insulin pens have also fueled the growth of this market. However, cost of production, manufacturing complexities and critical regulatory requirements for the approval of biotechnology derived products are the factors that could hinder the growth of global human insulin market. Pipeline insulin products and untapped emerging economies are the promising opportunities for the manufacturers of global human insulin.

Enquire for customization of report: https://www.alliedmarketresearch.com/request-for-customization/417

Global Human Insulin Market by Types: The global human insulin market is segmented by product type into Traditional and Modern Human Insulin. Traditional Human Insulin is segmented as Premixed, Intermediate Acting and Short Acting Human Insulin, whereas Modern Human Insulin includes Premixed, Long Acting and Rapid Acting types. Long acting modern insulin and premixed modern insulin are the fastest growing categories of this segment.

Send Enquiry About Report: https://www.alliedmarketresearch.com/purchase-enquiry/417

Global Human Insulin Market by Brands: According to the brands available into the market, the global human insulin market is classified as traditional and modern human insulin brands. Traditional brands include Humulin, Actrapid and Insuman, whereas, modern brands include Humalog, Novomix, Novorapid, Lantus, Levemir and Apidra. Over the past few years, biosimilars has gained popularity in comparison to branded drugs. Basalog, Wosulin and Glaritus are the biosimilars available in Asia-Pacific region. Amongst traditional and modern brands, Lantus holds the largest market share, whereas, Levemir and Apidra are the fastest growing insulin drugs.

Browse full report @ https://www.alliedmarketresearch.com/human-insulin-market

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions”. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Human Insulin

Posted on

The report also provides market size and forecast for testing devices used for carrying such tests. The market for STD testing devices was valued at $7.7 billion in 2013 with laboratory testing devices accounted for the most of the market and PoC devices shall grow at the fastest rate.

STD Testing Market (Sexually Transmitted Diseases Testing Market) Report, published by Allied Market Research, forecasts that the global market is expected to garner $167.4 billion by 2020, registering a CAGR of 8.5% during the period 2014-2020.The growth in the market is chiefly attributed to the high growth in HIV and HPV testing, especially in Asia Pacific and African regions along with complimenting growth rate of the European market.

View Detail Summary of this report:https://www.alliedmarketresearch.com/diagnostic-testing-stds-market

Sexually transmitted diseases or venereal diseases (VDs) are one of the most critical health challenges facing the world today. Rising rates of incidence of fatal STDs, corresponding high-economic burden and consequent implementation of Provider-Initiated Counselling and Testing (PICT) and Client-Initiated Counselling and Testing (CICT) are factors that drive the growth of the diagnostic testing market for STDs. Clinical manifestations of STD, for example, Chlamydia range from arthritis, Epididymitis, Orchitis, Infertility in men to Cervicitis, Endometritis, Salpingitis, PID, infertility and Perihepatitis in women; and untreated STDs that display such manifestations are often fatal. The risk of transmission of Chlamydia infection from an infected male to a female partner is estimated to be about 40% and from an infected female to male is about 30%. Such high rates of transmission, coupled with high rate of undiagnosed and untreated cases (about 85% of women and 40% of men are asymptomatic), renders huge economic burden on healthcare departments across all countries. To ameliorate such cases, healthcare departments across the world, have initiated national screening and also incentivized voluntary screening. Overall, the afore-mentioned factors result in high testing volume for Chlamydia, which contributes to a larger market share in terms of value. HIV, is incurable and prognosis of HIV leads to numerous infections that result in fatality. HIV infected patients also suffer from other co-infections; HIV and Syphilis have a high co-infection rate of about 25%. Akin to national and voluntary screening implemented for Chlamydia, many healthcare departments implemented CICT and PICT screening for HIV too. Such screening programs are expected to increase HIV testing volumes, which is estimated to reach 2.1 billion by 2020.

Laboratory testing of STDs is significant, despite of the presence of many point-of-care (PoC) testing kits available. Some of the STDs are not diagnosed with point of care methods. For instance, HSV (Herpes Simplex Virus), low-risk HPV (Human Papilloma Virus) and Chancroid that manifest as ‘warts’ on the patient’s skin, require physical examination by the laboratory experts. Also, many of the POC testing devices are not yet approved by the regulatory health authorities such as USFDA, owing to deviations in the sensitivity and specificity criteria. For these reasons, laboratory testing is considered to be most reliable and globally accepted method for STD testing; therefore, garners a comparatively larger market share than POC testing.

Key findings of Sexually Transmitted Diseases (STDs) Testing Market:

  • Global market for diagnostic testing of STDs is gaining traction with growth in HIV and HPV screening and laboratory testing
  • HIV testing market segment would grow at a CAGR of 10.9% during the forecast period
  • Europe would be one of the lucrative markets in terms of growth. The European STDs testing market would reach $26.8 billion by 2020, with the highest CAGR of 13.5% (as compared to other regional markets)
  • HPV testing volume and revenue will grow at much faster rate owing to higher incidences in Asia Pacific region

As elaborated earlier, many healthcare institutions provide diagnostic testing services for STDs, such as specialized STD clinics, Genito Urinary Medicine (GUM) clinics along with general hospitals, government laboratories and private diagnostic centers. The afore-mentioned thus constitute key market participants of the global diagnostic testing of STDs market. Along with the testing service providers, many companies provide devices such as laboratory instruments and POC testing kits/devices for VDs. Companies profiled in this report are Roche Holdings AG, Bio Merieux, Hologic Inc.,Becton Dickinson& Company, Cepheid Inc., Danaher Corporation, Affymetrix, Alere Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., and DiaSorin.

Anti-inflammatory Therapeutics Market is Expected to Reach $106.1 Billion

Posted on

According to a new report by Allied Market Research, titled, “Global Anti-inflammatory Therapeutics Market – Size, Share, Trend, Company Profiles, Demand, Insights, Analysis, Opportunities, Segmentation, and Forecast, 2014-2020”, the global anti-inflammatory therapeutics market is expected to grow at a CAGR of 5.9% from 2015 to 2020. The anti-inflammatory biologics segment held 3/5th of overall market in 2014. The Asia Pacific market would exhibit the highest CAGR of 8.5% during the forecast period.

Inflammation is the mechanism of innate immunity, which eliminates the cause of injury. Sometimes, the body’s defense system inappropriately triggers inflammation against its own cells, resulting in inflammatory autoimmune diseases. Reducing inflammation is one of the primary therapeutic strategies in acute as well as chronic diseases such as arthritis, psoriasis, and asthma. The rising incidences of autoimmune and respiratory conditions, extensive drug development pipeline, and increasing popularity of anti-inflammatory drugs with lesser side effects are the key factors driving the growth of the global anti-inflammatory therapeutics market. In addition, growing awareness about anti-inflammatory therapeutics and government initiatives, in the Asia pacific and LAMEA would further boost the market growth. However adverse effects associated with long term consumption of drugs namely NSAIDs and Corticosteroids would limit the market growth to a certain extent.

To view the report, visit the website at https://www.alliedmarketresearch.com/anti-inflammatory-therapeutics-market

The anti-inflammatory biologics hold the largest market share in 2014 and would also exhibit highest growth rate over the forecast period. This is due to the emergence of targeted anti-inflammatory biologics and biosimilars with lesser side effects. Market share of corticosteroids is projected to decrease by 2020, primarily due to withdrawal syndromes. Among indication market, arthritis would continue to lead through 2020 due to high incidence rate and preference of anti-inflammatory biologics for the treatment of arthritis.

Key findings of the study:

  • Arthritis indication was the major revenue generating segment in the global anti-inflammatory therapeutics market in 2014 followed by respiratory diseases
  • Psoriasis segment is the projected to grow at a CAGR of 8.1%, fastest among all
  • North America would continue to lead the market through 2020, currently accounts for about half of the global revenue
  • The U.S. accounted for about 5/6th of the North America anti-inflammatory therapeutics market revenue in 2014
  • Asia-Pacific is projected to be the fastest growing market

Get Free Sample of This Report at: http://bit.ly/1L5ItiD

In developed economies, such as North America and Europe, branded drugs are preferred over generics whereas there has been a reverse trend in developing economies. This is evident from the fact that about 50% of the anti-inflammatory biologics market has its presence in the North America, whereas, Asia Pacific and LAMEA collectively accounted for 35% share in NSAIDs market as compared to about just 25% share in branded biologics market in 2014.

Companies are adopting drug pipeline development and product launch as key strategies to overcome patent expiries of existing drugs and gain additional market shareKey companies profiled in the report are Pfizer Inc., Abbvie Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc. Novartis, F. Hoffman La Roche AG, Eli Lily and Company, AstraZeneca PLC .and Amgen

Ask Questions To The Experts @ http://bit.ly/1O9EsL9

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions”. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
Deep Joshi
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Int’l: +1 (503) 505-6949
Toll Free: + 1-800-792-5285 (U.S. & Canada)
E-mail: sales@alliedmarketresearch.com